Departments of Radiopharmaceutical Cancer Research

Radionuclide Theragnostics, Dr. Hans-Jürgen Pietzsch

• Therapeutic Alpha-Emitters
• Multi-targeted Radiotheranostics
• Biological evaluation and modulation of targeted, radiometal-based bioconjugates
• Bispidine-based Radiotheranostics
• Preclinical Characterization of Radioconjugates
• Cyclotron-based Production of Radiometalnuclides

Radioimmunology, Dr. Anja Feldmann

• Antibody-based immunotherapeutics and diagnostics for therapy and imaging of tumors
• Cellular immunotherapeutics for an individualized immunotherapy and diagnostics
• Modulation of the tumor microenvironment via manipulation with regulatory T cells and checkpoint inhibitors
• Combination of immunotherapies with other tumor therapies (e.g. external or internal radiotherapy)
• Nano-Microsystems for life sciences

Radiopharmaceutical and Chemical Biology, Prof. Dr. Jens Pietzsch

• Radiotracer and Drug Development
• Theranostic Targets and Experimental Models
• Radiopharmacology and Cancer Imaging
• Tissue Regeneration and Inflammation Imaging

Positron Emission Tomography, Prof. Dr. Jörg van den Hoff

• Improved quantification of functional information in oncological PET
• Quantitative perfusion imaging using functional ASL-MRI
• Multimodal imaging and assessment of in vivo quantification accuracy
• Motion compensation methods for PET
• High resolution PET image reconstruction

Translational TME Ligands, Prof. Dr. Klaus Kopka

• Small molecule and peptide-based radiotracer for PET-imaging of TME receptors
• Radiolabeled near-infrared (NIR) fluorescence dyes for optical and radio imaging
• Combination with theranostic approaches (e.g. endoradiotherapy and radioimmunotherapy)

Radiopharmaceuticals Production, Dr. Torsten Knieß

• Generation of radioisotopes with cyclotron TR-Flex
• GMP-certified radiopharmaceuticals production and quality control
• Radioisotopes and radiotracer for preclinical application

Neuroradiopharmaceuticals, Prof. Dr. Peter Brust

• Molecular imaging of adenosine signalling in cancer
• Molecular imaging of α7 nAChR in cancer and brain diseases
• [¹⁸F]Flubatine - a potential PET marker of early Alzheimer`s disease
• Development of new ligands and ¹⁸F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
• New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
• Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
• Development of ¹⁸F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases